Entrada Therapeutics, Inc. (TRDA) Net Income (Loss) Attributable to Parent USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Entrada Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2024.
  • Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was $23.5 M.
  • Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was $23.5 M.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$6.69 M, a 92.9% increase from 2022.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$94.6 M, a 84.9% decline from 2021.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$51.2 M, a 92.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $23.5 M $23.5 M +$30.2 M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$6.69 M -$9.54 M +$15.1 M +61.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$21.8 M $35.5 M +$60.6 M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$82.4 M -$25.9 M -$2.75 M -11.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-07
Q1 2023 -$79.6 M -$6.67 M +$15 M +69.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$94.6 M -$24.6 M -$6.18 M -33.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$88.4 M -$25.1 M -$10.7 M -74.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$77.7 M -$23.2 M -$13.3 M -134% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$64.4 M -$21.7 M -$13.3 M -159% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$51.2 M -$18.4 M -$9.77 M -113% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$41.4 M -$14.4 M -$7.44 M -106% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$33.9 M -$9.9 M -$3.73 M -60.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$30.2 M -$8.38 M -$3.69 M -78.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$26.5 M -$8.67 M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 -$6.99 M Jul 1, 2020 Sep 30, 2020 10-Q 2021-12-09
Q2 2020 -$6.17 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-12-09
Q1 2020 -$4.69 M Jan 1, 2020 Mar 31, 2020 10-Q 2021-12-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.